FDA Probing Risk of Pancreatitis with Incretins

(MedPage Today) -- The FDA said Thursday it is reviewing unpublished data that point toward an increased risk of pancreatitis and precancerous changes in type 2 diabetes patients who are treated with drugs in the incretin class.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news